Incyte INCY
NASDAQ INCY
$127.18 +2.78 (+2.23%)
As of: Sep 9, 2026 · 2:26 PM EDT

Incyte (INCY) Restructuring Costs (2010 - 2016)

Incyte's (INCY) quarterly Restructuring Costs came in at $1.6 million in Q4 2016, up 6.67% quarter-over-quarter from $1.5 million in Q3 2016.

Analysis

Incyte (INCY) Restructuring Costs (2010 - 2016) Analysis & Trends

Incyte (INCY) has reported Restructuring Costs for 3 consecutive years, with $1.6 million the latest figure, recorded in Q4 2016.

  • For the quarter ending Q4 2016, Restructuring Costs changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2016 stood at $4.4 million (changed N/A YoY), and the FY2016 full-year result was $1.6 million, changed N/A from the prior year.
  • Restructuring Costs advanced to $1.6 million in Q4 2016 per INCY's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $1.6 million in Q4 2016 and bottomed at $1.3 million in Q2 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 646.71 Bn 625.95 Bn 17.26 Bn
2 AbbVie 442.22 Bn 435.65 Bn 12.70 Bn
3 Merck 366.92 Bn 359.78 Bn 12.21 Bn
4 Novartis Ag 266.90 Bn 259.21 Bn 11.24 Bn
5 Pfizer 159.20 Bn 147.50 Bn 10.94 Bn
6 Sanofi 52.44 Bn 45.06 Bn 10.79 Bn
7 Revolution Medicines 44.11 Bn 44.11 Bn -
8 Incyte 25.38 Bn 20.85 Bn 1.57 Bn
9 United Therapeutics 21.50 Bn 18.84 Bn 683.80 Mn
10 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 1.60 Mn
Sep 30, 2016 1.50 Mn
Jun 30, 2016 1.30 Mn
Jun 30, 2011 20,000.00
Mar 31, 2011 691,000.00
Dec 31, 2010 20,000.00
Sep 30, 2010 -139,000.00
Jun 30, 2010 -145,000.00
Mar 31, 2010 -115,000.00